These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1056 related items for PubMed ID: 11139588

  • 1. Phosphatidylinositol 3-kinase/AKT-mediated activation of estrogen receptor alpha: a new model for anti-estrogen resistance.
    Campbell RA, Bhat-Nakshatri P, Patel NM, Constantinidou D, Ali S, Nakshatri H.
    J Biol Chem; 2001 Mar 30; 276(13):9817-24. PubMed ID: 11139588
    [Abstract] [Full Text] [Related]

  • 2. Effect of estradiol on estrogen receptor-alpha gene expression and activity can be modulated by the ErbB2/PI 3-K/Akt pathway.
    Stoica GE, Franke TF, Moroni M, Mueller S, Morgan E, Iann MC, Winder AD, Reiter R, Wellstein A, Martin MB, Stoica A.
    Oncogene; 2003 Sep 11; 22(39):7998-8011. PubMed ID: 12970748
    [Abstract] [Full Text] [Related]

  • 3. Estradiol rapidly activates Akt via the ErbB2 signaling pathway.
    Stoica GE, Franke TF, Wellstein A, Czubayko F, List HJ, Reiter R, Morgan E, Martin MB, Stoica A.
    Mol Endocrinol; 2003 May 11; 17(5):818-30. PubMed ID: 12554767
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. MAP kinase/estrogen receptor cross-talk enhances estrogen-mediated signaling and tumor growth but does not confer tamoxifen resistance.
    Atanaskova N, Keshamouni VG, Krueger JS, Schwartz JA, Miller F, Reddy KB.
    Oncogene; 2002 Jun 06; 21(25):4000-8. PubMed ID: 12037682
    [Abstract] [Full Text] [Related]

  • 7. Resveratrol modulates the phosphoinositide 3-kinase pathway through an estrogen receptor alpha-dependent mechanism: relevance in cell proliferation.
    Pozo-Guisado E, Lorenzo-Benayas MJ, Fernández-Salguero PM.
    Int J Cancer; 2004 Mar 20; 109(2):167-73. PubMed ID: 14750165
    [Abstract] [Full Text] [Related]

  • 8. Keratinocyte growth factor (KGF) regulates estrogen receptor-alpha (ER-alpha) expression and cell apoptosis via phosphatidylinositol 3-kinase (PI3K)/Akt pathway in human breast cancer cells.
    Chang HL, Sugimoto Y, Liu S, Wang LS, Huang YW, Ye W, Lin YC.
    Anticancer Res; 2009 Aug 20; 29(8):3195-205. PubMed ID: 19661335
    [Abstract] [Full Text] [Related]

  • 9. A new selective AKT pharmacological inhibitor reduces resistance to chemotherapeutic drugs, TRAIL, all-trans-retinoic acid, and ionizing radiation of human leukemia cells.
    Martelli AM, Tazzari PL, Tabellini G, Bortul R, Billi AM, Manzoli L, Ruggeri A, Conte R, Cocco L.
    Leukemia; 2003 Sep 20; 17(9):1794-805. PubMed ID: 12970779
    [Abstract] [Full Text] [Related]

  • 10. Endocrine resistance associated with activated ErbB system in breast cancer cells is reversed by inhibiting MAPK or PI3K/Akt signaling pathways.
    Ghayad SE, Vendrell JA, Ben Larbi S, Dumontet C, Bieche I, Cohen PA.
    Int J Cancer; 2010 Jan 15; 126(2):545-62. PubMed ID: 19609946
    [Abstract] [Full Text] [Related]

  • 11. Resistance to gefitinib in PTEN-null HER-overexpressing tumor cells can be overcome through restoration of PTEN function or pharmacologic modulation of constitutive phosphatidylinositol 3'-kinase/Akt pathway signaling.
    She QB, Solit D, Basso A, Moasser MM.
    Clin Cancer Res; 2003 Oct 01; 9(12):4340-6. PubMed ID: 14555504
    [Abstract] [Full Text] [Related]

  • 12. Dual regulation of MMP-2 expression by the type 1 insulin-like growth factor receptor: the phosphatidylinositol 3-kinase/Akt and Raf/ERK pathways transmit opposing signals.
    Zhang D, Bar-Eli M, Meloche S, Brodt P.
    J Biol Chem; 2004 May 07; 279(19):19683-90. PubMed ID: 14993222
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Autocrine IGF-I/insulin receptor axis compensates for inhibition of AKT in ER-positive breast cancer cells with resistance to estrogen deprivation.
    Fox EM, Kuba MG, Miller TW, Davies BR, Arteaga CL.
    Breast Cancer Res; 2013 May 07; 15(4):R55. PubMed ID: 23844554
    [Abstract] [Full Text] [Related]

  • 16. Estrogen receptor β represses Akt signaling in breast cancer cells via downregulation of HER2/HER3 and upregulation of PTEN: implications for tamoxifen sensitivity.
    Lindberg K, Helguero LA, Omoto Y, Gustafsson JÅ, Haldosén LA.
    Breast Cancer Res; 2011 Apr 14; 13(2):R43. PubMed ID: 21492444
    [Abstract] [Full Text] [Related]

  • 17. Inhibition of phosphatidylinositol 3-kinase-Akt signaling blocks growth, promotes apoptosis, and enhances sensitivity of small cell lung cancer cells to chemotherapy.
    Krystal GW, Sulanke G, Litz J.
    Mol Cancer Ther; 2002 Sep 14; 1(11):913-22. PubMed ID: 12481412
    [Abstract] [Full Text] [Related]

  • 18. Tamoxifen induces the expression of maspin through estrogen receptor-alpha.
    Liu Z, Shi HY, Nawaz Z, Zhang M.
    Cancer Lett; 2004 Jun 08; 209(1):55-65. PubMed ID: 15145521
    [Abstract] [Full Text] [Related]

  • 19. Hyaluronan-mediated CD44 interaction with RhoGEF and Rho kinase promotes Grb2-associated binder-1 phosphorylation and phosphatidylinositol 3-kinase signaling leading to cytokine (macrophage-colony stimulating factor) production and breast tumor progression.
    Bourguignon LY, Singleton PA, Zhu H, Diedrich F.
    J Biol Chem; 2003 Aug 08; 278(32):29420-34. PubMed ID: 12748184
    [Abstract] [Full Text] [Related]

  • 20. Overcoming endocrine resistance due to reduced PTEN levels in estrogen receptor-positive breast cancer by co-targeting mammalian target of rapamycin, protein kinase B, or mitogen-activated protein kinase kinase.
    Fu X, Creighton CJ, Biswal NC, Kumar V, Shea M, Herrera S, Contreras A, Gutierrez C, Wang T, Nanda S, Giuliano M, Morrison G, Nardone A, Karlin KL, Westbrook TF, Heiser LM, Anur P, Spellman P, Guichard SM, Smith PD, Davies BR, Klinowska T, Lee AV, Mills GB, Rimawi MF, Hilsenbeck SG, Gray JW, Joshi A, Osborne CK, Schiff R.
    Breast Cancer Res; 2014 Sep 11; 16(5):430. PubMed ID: 25212826
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 53.